-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Tipifarnib in Myeloproliferative Disorders
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Tipifarnib in Myeloproliferative Disorders report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Tipifarnib in Myeloproliferative Disorders Drug Details: Tipifarnib (Zarnestra) is under development for...
-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – Aflibercept Biosimilar in Wet (Neovascular / Exudative) Macular Degeneration
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Aflibercept Biosimilar in Wet (Neovascular / Exudative) Macular Degeneration report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Aflibercept Biosimilar in Wet (Neovascular / Exudative)...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Ustekinumab Biosimilar in Ulcerative Colitis
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Ustekinumab Biosimilar in Ulcerative Colitis report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Ustekinumab Biosimilar in Ulcerative Colitis Drug Details: Ustekinumab biosimilar (FYB-202) is...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Ustekinumab Biosimilar in Crohn’s Disease (Regional Enteritis)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Ustekinumab Biosimilar in Crohn's Disease (Regional Enteritis) report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Ustekinumab Biosimilar in Crohn's Disease (Regional Enteritis) Drug Details:...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Ustekinumab Biosimilar in Plaque Psoriasis (Psoriasis Vulgaris)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Ustekinumab Biosimilar in Plaque Psoriasis (Psoriasis Vulgaris) report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Ustekinumab Biosimilar in Plaque Psoriasis (Psoriasis Vulgaris) Drug Details:...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Ustekinumab Biosimilar in Psoriatic Arthritis
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Ustekinumab Biosimilar in Psoriatic Arthritis report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Ustekinumab Biosimilar in Psoriatic Arthritis Drug Details: Ustekinumab biosimilar (FYB-202) is...
-
Product Insights
Psoriatic Arthritis – Drugs In Development, 2023
Global Markets Direct’s, ‘Psoriatic Arthritis - Drugs In Development, 2023’, provides an overview of the Psoriatic Arthritis pipeline landscape. The report provides comprehensive information on the therapeutics under development for Psoriatic Arthritis, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an...
-
Product Insights
Plaque Psoriasis (Psoriasis Vulgaris) – Drugs In Development, 2023
Global Markets Direct’s, ‘Plaque Psoriasis (Psoriasis Vulgaris) - Drugs In Development, 2023’, provides an overview of the Plaque Psoriasis (Psoriasis Vulgaris) pipeline landscape. The report provides comprehensive information on the therapeutics under development for Plaque Psoriasis (Psoriasis Vulgaris), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press...